Italia markets closed

FibroGen, Inc. (0IL8.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
11,93+0,93 (+8,45%)
Alla chiusura: 03:30PM BST

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200
https://www.fibrogen.com

Settore/i
Settore
Impiegati a tempo pieno566

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Enrique A. ConternoCEO & Director1,31MN/D1967
Mr. Juan GrahamChief Financial Officer377,44kN/D1976
Dr. Elias KouchakjiSr. VP of Clinical Devel., Drug Safety & PharmacovigilanceN/DN/D1956
Ms. Christine L. ChungSr. VP of China Operations1,01MN/D1968
Mr. Thane WettigChief Commercial Officer709,39kN/D1965
Dr. Mark Eisner M.D., M.P.H.Chief Medical Officer1,87MN/D1966
Dr. Barry A. Berkowitz Ph.D.FounderN/DN/DN/D
Dr. John J. Hunter Ph.D.Chief Scientific OfficerN/DN/D1963
Ms. Karen L. BergmanVP of Investor Relations & Corp. CommunicationsN/DN/DN/D
Mr. Michael D. Lowenstein J.D., Ph.D.Chief Legal OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di FibroGen, Inc. al 1 luglio 2022 è 9. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 2; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.